# Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

> **NCT04712721** · EARLY_PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Brain Neoplasms
- Gastroesophageal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** 68Ga-FF58

## Key facts

- **NCT ID:** NCT04712721
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-14
- **Primary completion:** 2024-06-18
- **Final completion:** 2024-07-01
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712721, "Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04712721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*